Recruiting Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997 Conditions Advanced Non-Small-Cell Lung Cancer, Bronchial Diseases, Bronchial Neoplasms, +14 more Locations USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States University of California Davis Comprehensive Cancer Center — Sacramento, California, United States UCSF Medical Center-Mission Bay — San Francisco, California, United States Kaiser Permanente Medical Center — Vallejo, California, United States View all 78 locations View more locations Show fewer locations Loading locations... View Trial Details
